Direct-acting antivirals ombitasvir/paritaprevir/rotonavir+dasabuvir with or without ribavirin in hepatitis C virus (HCV) genotype 1-infected treatment-naive or treatment-experienced patients with or without cirrhosis: real-life experience in Lithuania and Latvia

Background: The current international multicentre open-label, uncontrolled, real-world retrospective study aimed at evaluating the effectiveness and safety of ombitasvir / paritaprevir / ritonavir + dasabuvir ± ribavirin (3D therapy) in treatment-naive and treatment-experienced hepatitis C virus (HCV) genotype 1-infected (GT1) patients. Methods: Adult patients with chronic HCV GT1 infection, scheduled for 3D therapy according to therapeutic guidelines, were eligible. Demographic and clinical data were collected retrospectively by reviewing individuals health records. The primary effectiveness endpoint was the sustained virological response at 12 weeks following the end of treatment (SVR12).…